Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 27;3(1):e000282.
doi: 10.1136/esmoopen-2017-000282. eCollection 2018.

Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins

Anna Torgeson  1 , Ignacio Garrido-Laguna  2 , Randa Tao  1 , George M Cannon  3 , Courtney L Scaife  4 , Shane Lloyd  1
Affiliations

Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins

Anna Torgeson et al. ESMO Open. .

Abstract

Background: Surgical resection remains the best chance at long-term survival in pancreatic cancer, though margin-positive resections are associated with diminished survival. We examined the effect of margin-positive resection on survival, as well as the role and timing of additional therapies through the National Cancer Database (NCDB).

Patients and methods: Patients with stage IIA-III pancreatic adenocarcinoma diagnosed from 2004 to 2013 were identified in NCDB. Survival was compared using univariate and multivariate Cox proportional hazards modelling for patients who underwent surgery with negative (R0), microscopically positive (R1) and macroscopically positive (R2) margins or non-surgical treatment. We further analysed patients by margin status, timing of additional therapy (neoadjuvant therapy (NAT) vs adjuvant therapy (AT) vs none) and clinical stage.

Results: We analysed 44 852 patients. Median survival (MS) for patients who did not undergo surgery was 10.3 months, compared with 19.7 months for R0 (P<0.001), 14.3 months for R1 (P<0.001) and 9.8 months (P=0.07) for R2 resections. NAT (MS 23.2 months) was associated with improved survival compared with AT (MS 21.5 months) in negative-margin patients and equivalent (MS 17.6 months) to AT (MS 16.8 months) in positive-margin patients. Survival for stage III NAT positive-margin patients (MS 19.8 months) was equivalent to AT after negative margins (MS 18.4 months, P=1.00). Improved R0 rates were seen with NAT (88% vs 81%, P<0.001), especially in stage III patients (85% vs 59%, P<0.001).

Conclusion: R1 resections portend poorer survival than R0 but do not negate the benefit of surgery when additional therapy is given. NAT was associated with improved R0 rates and improved survival for stage III positive-margin patients.

Keywords: NCDB; pancreatic cancer; surgical margins.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Overall survival by margin status and surgical resection.
See this image and copyright information in PMC

References

    1. Neoptolemos JP, Stocken DD, Friess H, et al. . A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200–10. 10.1056/NEJMoa032295 - DOI - PubMed
    1. Hsu CC, Herman JM, Corsini MM, et al. . Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010;17:981–90. 10.1245/s10434-009-0743-7 - DOI - PMC - PubMed
    1. Oettle H, Neuhaus P, Hochhaus A, et al. . Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310:1473–81. 10.1001/jama.2013.279201 - DOI - PubMed
    1. Butturini G, Stocken DD, Wente MN, et al. . Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008;143:75–83. 10.1001/archsurg.2007.17 - DOI - PubMed
    1. Stocken DD, Büchler MW, Dervenis C, et al. . Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005;92:1372–81. 10.1038/sj.bjc.6602513 - DOI - PMC - PubMed

LinkOut - more resources